Alloantibodies and Allograft Arteriosclerosis Accelerated Adversity Ahead ? Richard


In this issue, Loupy et al report that, among renal allograft recipients who develop antidonor alloantibody, a subset that exhibit severe arteriosclerosis in the graft within the first year after transplant are at significantly increased risk to incur a major adverse cardiovascular event (MACE) or die during subsequent intermediate term (minimum follow-up, 3.4 years and median follow-up, >5 years). The observations in a singlecenter renal transplant data set derived from a study population of >744 patients (of 1012 transplanted between 2004 and 2009, with complete data beyond 1 year in 664) were largely confirmed in a second independent cohort of 321 consecutive patients (2006–2009) from another center in the same city who met study entry criteria. To tease out accelerated [graft] arteriosclerosis as an independent risk factor, 33 previously identified donor and recipient factors were taken into account in their statistical model. This careful, detailed analytic approach reflects considerable effort, which is clearly necessary and perhaps sufficient to justify confidence that the association they identify is biologically meaningful.

2 Figures and Tables

Cite this paper

@inproceedings{Bromberg2015AlloantibodiesAA, title={Alloantibodies and Allograft Arteriosclerosis Accelerated Adversity Ahead ? Richard}, author={Simon Bromberg}, year={2015} }